Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

NCT04556539 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Ovarian Cancer

Interventions

DRUG: SC10914

Sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd.